Joe Biden’s Prostate Cancer Diagnosis Raises Concerns

Joe Biden’s recent diagnosis of prostate cancer has sparked accusations from some conservatives about a possible cover-up. However, experts in oncology argue that screening limitations could explain the delayed detection. It’s important to recognize that even with top-notch medical care, prostate cancer can sometimes be missed.

The 82-year-old received his diagnosis last week following urinary issues and the discovery of a nodule in his prostate, as stated by his office. This revelation has led to varied reactions, with former President Donald Trump expressing sadness over Biden’s condition. Meanwhile, a group of Republican leaders, including Vice President JD Vance and Donald Trump Jr., have suggested that Biden’s medical team might have concealed his illness for political reasons.

Biden’s health has been under scrutiny for months, especially during his presidency and the early stages of his reelection campaign. This latest news also coincides with an upcoming book that reportedly addresses concerns about his health.

Prostate cancer, which is the most common type of cancer in men, is typically diagnosed much earlier than many other cancers. Blood tests measuring prostate-specific antigen (PSA) can often detect the disease in its early stages.

An expert consulted by AFP mentioned that, even with advanced medical treatment, it’s not unusual for cases of advanced cancer to be diagnosed late. “We cannot rule out the possibility that it may be a rapidly developed and aggressive form,” said Natacha Naoun, an oncologist at the Gustave-Roussy Institute in France.

Interestingly, annual PSA screening is not universally recommended for men over 70. The US Task Force on Preventive Services has noted that the risks of false positives and the complications of biopsies and treatments may outweigh their benefits.

It’s possible that Biden had opted out of yearly PSA checks, according to Russell Patchinski, an oncologist at Washington University in St. Louis. He highlighted that many prostate cancer patients do not necessarily exhibit noticeable symptoms.

Patchinski also mentioned that Biden could have undergone routine screenings that did not reveal any issues. “Maybe he was unlucky that his particular cancer did not express many PSAs,” he suggested. “In such a case, biopsies wouldn’t be done unless there were clear symptoms.”

Furthermore, Otis Brawley, an oncologist and epidemiologist at Johns Hopkins University, noted the limitations of current screening methods. “It’s not uncommon for men to be diagnosed with metastatic prostate disease even when undergoing standard annual screenings,” he stated, emphasizing the challenges still faced in accurately diagnosing this type of cancer.